Plus Therapeutics has begun technology transfer and manufacturing activities at SpectronRx to support late-stage clinical production of Rhenium-186 and Reyobiq (rhenium Re186 obisbemeda). Reyobiq is an innovative, injectable radiotherapy designed to deliver targeted, high-dose radiation directly to tumors within the central nervous system (CNS).
SpectronRx’s facility in Indiana will serve as a second GMP-compliant site, supplementing existing production at Radiomedix. This partnership enables on-demand manufacturing by consolidating the production of the Rhenium-186 isotope and the final drug product at a single location. Reyobiq is currently undergoing three separate clinical trials targeting recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.
Plus Therapeutics’ leadership stated that the technology transfer encompasses isotope processing, analytical methods, and regulatory expertise essential for commercial-scale output. With a 2026 milestone to complete manufacturing scale-up, the collaboration aims to bolster readiness for late-stage clinical supply, potentially offering a more precise treatment option with fewer off-target risks for CNS cancer patients compared to standard therapies.